Nimish Shah
Psychiatric/Mental Health, Adult · Framingham, MANPI 1023058328
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,135 of the $3,698 with a category attached, or 84.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health, adult clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $34.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$563
- Neurocrine Biosciences, Inc.$562
- Johnson & Johnson$349
- Otsuka America Pharmaceutical, Inc.$346
- Ironshore Pharmaceuticals Inc.$341
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$292
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$56315%
- Food & beverage$3,13585%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $563 |
| Neurocrine Biosciences, Inc. | 15 | $562 |
| Johnson & Johnson | 3 | $349 |
| Otsuka America Pharmaceutical, Inc. | 13 | $346 |
| Ironshore Pharmaceuticals Inc. | 6 | $341 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $292 |
| Collegium Pharmaceutical, Inc. | 4 | $238 |
| AbbVie | 11 | $195 |
| Neos Therapeutics, LP | 9 | $186 |
| Lundbeck LLC | 8 | $156 |
| Corium, LLC | 6 | $103 |
| Alkermes, Inc. | 4 | $80 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Tris Pharma Inc | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JORNAY PM$431
- SPRAVATO$125
- INVEGA SUSTENNA$125
- ABILIFY MAINTENA$113
- ABILIFY ASIMTUFII$113
- INGREZZA$104
How this compares
$3,698 in reported general payments places this provider in the 90th percentile of 92 psychiatric/mental health, adult providers in Massachusetts.
See all psychiatric/mental health, adult providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 12 | $34,016 |
| Duloxetine Hcl | 24 | $1,408 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $855 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 23 | $833 |
| Buspirone Hcl | 12 | $819 |
| Bupropion XlBupropion Hcl | 29 | $797 |
| Fluoxetine Hcl | 28 | $537 |
| Escitalopram Oxalate | 20 | $388 |
| Lamotrigine | 18 | $308 |
| Trazodone Hcl | 25 | $266 |
| Quetiapine Fumarate | 20 | $245 |
| Aripiprazole | 11 | $181 |
| Clonazepam | 26 | $67 |
| Lorazepam | 19 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $346 | $34,01612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 psychiatric/mental health, adult providers in Massachusetts.
Other psychiatric/mental health, adult in Framingham
- Karen ChesleyWoburn$16K
- Maria GrotzOrleans$6K
- Beverly AndersonAmesbury$5K
- Rosemarie PaoliniBrockton$5K
- Catherine JaffeArlington$4K
- Sheryl GoodallBrockton$4K
- Pamela MatthewsBourne$3K
- Meaghan RudolphMelrose$3K
- Anne BatemanHyannis$3K
- Michael PizzaActon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.